Ginsberg HN, et al. - From five placebo-controlled phase 3 studies, data from up to seventy-eight weeks were analyzed in people on maximally tolerated background statin to evaluate alirocumab efficacy and safety in people with/without diabetes mellitus (DM). In three studies, alirocumab 75 mg every 2 weeks (Q2W) was increased to 150 mg Q2W at week 12 if week 8 low-density lipoprotein cholesterol (LDL-C) was ≥ 70 mg/dL. Two studies used alirocumab 150 mg Q2W throughout. In people with/without diabetes mellitus, DM status does not seem to meaningfully affect lipid-modifying efficacy or safety of alirocumab treatment, nor does alirocumab seem to significantly affect blood glucose control.